Zentalis Pharmaceuticals Income Statement (2019-2026) | ZNTL

Income Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
40.56M26.86M
Operating items
Research & Development (Quarter)
44.77M54.00M38.44M46.11M43.83M42.18M40.62M48.58M42.68M46.77M51.56M49.59M48.39M36.82M32.97M27.25M27.61M22.95M29.49M28.72M
Selling, General & Administrative (Quarter)
10.36M8.87M9.75M11.77M19.64M12.01M11.14M16.37M15.66M15.95M16.36M15.74M16.76M14.61M40.01M10.58M8.45M10.78M7.91M9.14M
Restructuring Costs (Quarter)
7.80M
Other Operating Expenses (Quarter)
45.57M3.74M
Operating Expenses (Quarter)
55.13M62.87M48.19M57.88M63.46M54.19M51.75M64.95M103.92M62.72M67.92M65.33M65.15M51.43M76.71M45.62M36.06M33.73M37.39M37.85M
Operating Income (Quarter)
-55.13M-62.87M-48.19M-57.88M-63.46M-54.19M-51.75M-64.95M-103.92M-62.72M-67.92M-24.77M-65.15M-51.43M-49.85M-45.62M-36.06M-33.73M-37.39M-37.85M
EBIT (Quarter)
-55.13M-62.87M-48.19M-57.88M-63.46M-54.19M-51.75M-64.95M-103.92M-62.72M-67.92M-24.77M-65.15M-51.43M-49.85M-45.62M-36.06M-33.73M-37.39M-37.85M
Non-operating items
Interest & Investment Income (Quarter)
0.12M0.10M0.09M0.43M0.42M1.91M3.23M4.11M4.45M7.21M6.85M34.95M-22.86M11.25M2.17M-2.66M9.18M7.04M2.62M2.62M
Net income details
EBT (Quarter)
-55.02M-11.19M-48.10M-57.45M-63.04M-52.29M-48.52M-60.84M-99.47M-55.51M-61.07M10.18M-88.01M-40.19M-47.68M-48.28M-26.87M-26.69M-34.77M-35.23M
Tax Provisions (Quarter)
0.04M-0.70M0.16M0.03M0.02M-0.16M-0.36M0.11M-0.60M0.03M-0.14M0.14M0.27M-0.03M-0.20M0.44M0.12M
Profit After Tax (Quarter)
-54.57M-4.19M-50.06M-59.24M-68.36M-54.50M-54.68M-63.26M-112.53M-55.54M-60.83M10.07M-88.28M-40.16M-47.47M-48.28M-26.87M-26.69M-35.22M-35.35M
Equity Income (Quarter)
-1.83M-1.75M-5.34M-2.37M-6.82M-2.31M-13.70M
Net Income - Minority (Quarter)
-0.53M-0.22M-0.18M-0.14M-0.13M-0.11M
Income from Non-Controlling Interests (Quarter)
-0.49M-6.30M-0.04M-0.16M-0.04M-0.10M-0.01M-0.04M-0.04M-0.01M-0.02M-0.03M
Income from Continuing Operations (Quarter)
-55.06M-10.49M-48.26M-57.49M-63.05M-52.13M-48.16M-60.95M-98.86M-55.54M-60.94M10.04M-88.28M-40.16M-47.47M-48.28M-26.87M-26.69M-35.22M-35.35M
Consolidated Net Income (Quarter)
-55.06M-10.49M-48.26M-57.49M-63.05M-52.13M-48.16M-60.95M-98.86M-55.54M-60.94M10.04M-88.28M-40.16M-47.47M-48.28M-26.87M-26.69M-35.22M-35.35M
Income towards Parent Company (Quarter)
-55.06M-10.49M-48.79M-57.49M-63.05M-52.13M-48.38M-61.13M-99.00M-55.67M-61.05M10.04M-88.28M-40.16M-47.47M-48.28M-26.87M-26.69M-35.22M-35.35M
Net Income towards Common Stockholders (Quarter)
-55.06M-10.49M-48.79M-57.49M-63.05M-52.13M-48.38M-61.13M-99.00M-55.67M-61.05M10.04M-88.28M-40.16M-47.47M-48.28M-26.87M-26.69M-35.22M-35.35M
Additional items
EPS (Basic) (Quarter)
-1.34-0.09-1.11-1.31-1.34-0.96-0.92-1.07-1.85-0.79-0.830.14-1.24-0.56-0.66-0.67-0.37-0.37-0.49-0.50
EPS (Weighted Average and Diluted) (Quarter)
-1.34-0.09-1.11-1.31-1.34-0.96-0.92-1.07-1.85-0.79-0.830.14-1.24-0.56-0.66-0.67-0.37-0.37-0.49-0.50
Shares Outstanding (Weighted Average) (Quarter)
40.55M41.92M42.69M45.24M51.12M56.81M52.86M59.28M60.79M63.60M65.41M70.90M70.97M71.11M71.08M71.68M71.99M72.14M71.87M70.26M
Shares Outstanding (Diluted Average) (Quarter)
40.55M41.92M42.69M45.24M48.20M51.10M52.86M59.28M60.79M70.61M65.41M71.19M71.04M71.11M71.08M71.68M71.84M71.94M71.87M70.26M
EBITDA (Quarter)
-55.13M-62.87M-48.19M-57.88M-63.46M-54.19M-51.75M-64.95M-103.92M-62.72M-67.92M-24.77M-65.15M-51.43M-49.85M-45.62M-36.06M-33.73M-37.39M-37.85M
Interest Expenses (Quarter)
Shares Outstanding (Quarter)
41.31M45.20M45.49M45.58M56.97M57.00M59.28M59.44M70.60M70.64M70.77M71.01M71.11M71.15M71.28M71.95M72.14M72.25M69.09M71.16M
Tax Rate (Quarter)
-0.086.23-0.33-0.06-0.030.300.74-0.180.61-0.060.221.40-0.300.070.43-1.27-0.34